P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE

A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, C. Norregaard, S. Dimitrijević, E. Sullivan, M. Louie-Gao, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, A. Chin, S. R. Sendhil, M. S. Duh, P. Valent, D. J. DeAngelo

Open source

DOI: 10.1097/01.hs9.0000846924.89785.04
Published: 2022-06
Container: HemaSphere
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/01.hs9.0000846924.89785.04,
  title = {P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE},
  author = {A. Reiter and J. Gotlib and I. Álvarez-Twose and D. H. Radia and J. Luebke and P. J. Bobbili and A. Wang and C. Norregaard and S. Dimitrijević and E. Sullivan and M. Louie-Gao and J. Schwaab and I. A. Galinsky and C. Perkins and W. R. Sperr and P. Sriskandarajah and A. Chin and S. R. Sendhil and M. S. Duh and P. Valent and D. J. DeAngelo},
  year = {2022},
  journal = {HemaSphere},
  doi = {10.1097/01.hs9.0000846924.89785.04},
  url = {https://doi.org/10.1097/01.hs9.0000846924.89785.04}
}

RIS

TY  - JOUR
TI  - P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
AU  - A. Reiter
AU  - J. Gotlib
AU  - I. Álvarez-Twose
AU  - D. H. Radia
AU  - J. Luebke
AU  - P. J. Bobbili
AU  - A. Wang
AU  - C. Norregaard
AU  - S. Dimitrijević
AU  - E. Sullivan
AU  - M. Louie-Gao
AU  - J. Schwaab
AU  - I. A. Galinsky
AU  - C. Perkins
AU  - W. R. Sperr
AU  - P. Sriskandarajah
AU  - A. Chin
AU  - S. R. Sendhil
AU  - M. S. Duh
AU  - P. Valent
AU  - D. J. DeAngelo
PY  - 2022
JO  - HemaSphere
DO  - 10.1097/01.hs9.0000846924.89785.04
UR  - https://doi.org/10.1097/01.hs9.0000846924.89785.04
ER  -

APA

Reiter, A., Gotlib, J., Álvarez-Twose, I., Radia, D. H., Luebke, J., Bobbili, P. J., Wang, A., Norregaard, C., Dimitrijević, S., Sullivan, E., Louie-Gao, M., Schwaab, J., Galinsky, I. A., Perkins, C., Sperr, W. R., Sriskandarajah, P., Chin, A., Sendhil, S. R., Duh, M. S., Valent, P., & DeAngelo, D. J. (2022). P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE. HemaSphere. https://doi.org/10.1097/01.hs9.0000846924.89785.04

Source records

crossref · retrieved 2026-09-27T05:26:44.425Z